VFA
HUMA icon

Valeo Financial Advisors’s Humacyte HUMA Stock Holding History

Valeo Financial Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.5K Buy
19,900
+5,000
+34% +$4.63K ﹤0.01% 830
2026
Q1 		$9.04K Hold
14,900
– – ﹤0.01% 748
2025
Q4 		$14.3K Hold
14,900
– – ﹤0.01% 830
2025
Q3 		$25.9K Sell
14,900
-500
-3% -$980 ﹤0.01% 815
2025
Q2 		$32.2K Buy
+15,400
New +$29.6K ﹤0.01% 760
2021
Q2 		– Sell
-400
Closed -$4K – 1092
2021
Q1 		$4K Buy
+400
New +$4.37K ﹤0.01% 1623

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Valeo Financial Advisors's HUMA Position: Q2 2026 in Review

Valeo Financial Advisors increased its Humacyte (HUMA) stake by 34% in Q2 2026, buying an estimated $4.63K and bringing the position to 19,900 shares worth $15.5K. The position accounts for ﹤0.01% of the portfolio, ranked #830.

Valeo Financial Advisors first reported a position in HUMA in Q1 2021 and has held it in 6 quarters since. The position peaked at $32.2K in Q2 2025. 163 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Valeo Financial Advisors held 19,900 shares of Humacyte worth $15.5K as of Q2 2026.
  • Valeo Financial Advisors bought 5,000 Humacyte shares in Q2 2026, an estimated $4.63K.
  • Humacyte made up ﹤0.01% of Valeo Financial Advisors's portfolio in Q2 2026, its #830 holding.
  • Valeo Financial Advisors first reported a position in Humacyte in Q1 2021 and has held it in 6 quarters since.
  • Valeo Financial Advisors's Humacyte position peaked at $32.2K in Q2 2025.
  • 163 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Valeo Financial Advisors's 13F filing for Q2 2026, filed 8 Jul 2026.